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CLL/SLL: chronic lymphocytic leukemia and small lymphocytic leukemia  
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Short Report, Cancer Epidemiology 
 
Novelty and impact statements (Words=85) 
Do lifestyle factors affect lymphoma risk? Previous studies have been inconclusive, and most 
lacked statistical power to allow accurate conclusions. In this large, prospective European 
study, the authors examined the relationship between a score combining lifestyle exposures, 
such as smoking, BMI, and alcohol, and the risk of lymphoma. They observed that healthy 
behaviors were inversely related to the risk of Hodgkin lymphoma, although smoking was the 
main driver of the association. These findings indicated a limited role for lifestyle factors in 
the etiology of lymphomas. 
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Abstract (Words = 248) 
Limited evidence exists on the role of modifiable lifestyle factors on the risk of lymphoma. In 
this work, the associations between adherence to healthy lifestyles and risks of Hodgkin 
lymphoma (HL) and non-Hodgkin lymphoma (NHL) were evaluated in a large-scale European 
prospective cohort. Within the European Prospective Investigation into Cancer and Nutrition 
(EPIC), 2,999 incident lymphoma cases (132 HL and 2,746 NHL) were diagnosed among 
453,808 participants after 15 years (median) of follow-up. The healthy lifestyle index (HLI) 
score combined information on smoking, alcohol intake, diet, physical activity and BMI, with 
large values of HLI expressing adherence to healthy behavior. Cox proportional hazards models 
were used to estimate lymphoma hazard ratios (HR) and 95% confidence interval (CI). 
Sensitivity analyses were conducted by excluding, in turn, each lifestyle factor from the HLI 
score. The HLI was inversely associated with HL, with HR for a 1-standard deviation (SD) 
increment in the score equal to 0.78 (95%CI: 0.66, 0.94). Sensitivity analyses showed that the 
association was mainly driven by smoking and marginally by diet. NHL risk was not associated 
with the HLI, with HRs for a 1-SD increment equal to 0.99 (0.95, 1.03), with no evidence for 
heterogeneity in the association across NHL subtypes. In the EPIC study, adherence to healthy 
lifestyles was not associated with overall lymphoma or NHL risk, while an inverse association 
was observed for HL, although this was largely attributable to smoking. These findings suggest 
a limited role of lifestyle factors in the etiology of lymphoma subtypes. 
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Introduction (Words = 2,481) 
Lymphoma comprises a heterogeneous group of malignancies occurring in the lymphatic 
system, traditionally grouped as Hodgkin (HL) and non-Hodgkin lymphoma (NHL),1 which 
accounts for about 3.2% of cancers worldwide.2 During recent decades, lymphomas incidence 
rates increased with relatively higher rates in high-income countries2 and significant disparities 
among ethnic groups,3 suggesting an influence of lifestyle factors in lymphomagenesis that are 
more prevalent in the Western world.  
Although the roles of lifestyle factors have been extensively investigated in association with 
solid neoplasms, evidence on lymphoma risk remains unclear.4 Obesity and alcohol 
consumption have been most consistently associated with lymphoma, with positive5 and 
inverse6 relationships, respectively. However, most studies, predominantly case-control, faced 
differential recall bias for the assessment of lifestyle habits and sample size limitations for the 
investigation of lymphoma subtypes. Additionally, lifestyle factors were often evaluated 
independently in etiological models.  
In this study, a set of modifiable exposures, including smoking, alcohol intake, dietary habits, 
body mass index (BMI), and physical activity were combined into the Healthy Lifestyle Index 
(HLI) to reflect adherence to healthy habits. The HLI was previously related to the risks of site-
specific and overall cancers in prospective studies.7 In this analysis, associations between the 
HLI and lymphoma risks were examined within the EPIC study. The contributing role of each 
component of the HLI to lymphoma risk was also investigated. 
 
Methods 
Study population. EPIC is a multicenter prospective study designed to investigate the etiology 
of cancer in relation to diet and lifestyle factors. From 1992 to 2000, a total of 521,324 
participants (70% women, 35–70 years of age at baseline) were recruited in 10 European 
countries, mostly from the general population, as explained previously.8 In France, Norway, 
Utrecht and Naples, only women were recruited. Approval was obtained from IARC and 
participating institutions’ ethical review boards and participants provided informed consent 
before completing questionnaires at baseline.  
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Ascertainment of outcome. Cancer cases were identified during follow-up based on population 
cancer registries in Denmark, Italy, Netherlands, Spain, Sweden, Norway and the United 
Kingdom, and on a combination of methods, including health insurance records, cancer and 
pathology registries, and active follow-up of EPIC participants and their next of kin in France, 
Naples, Germany, and Greece. Clinical and morphological data were standardized using a 
common protocol across centers.8 Mortality data were collected from cancer or mortality 
registries at the regional or national level.  
The most recent vital status and cancer diagnosis update was used. Vital status was known for 
98.4% of all EPIC subjects while 1.6% of participants had emigrated, withdrawn or were lost 
to follow-up. The follow-up period ended between June 2008 and December 2012 depending 
on the recruitment centers.7 
Diagnoses of primary incident lymphoma cases were classified based on the International 
Classification of Diseases Oncology, 3rd edition (ICD-O-3), and grouped according to 
recommendations of the InterLymph Pathology Working Group,1 as: Hodgkin lymphoma (HL), 
non-Hodgkin lymphoma (NHL) and lymphoma not otherwise specified (NOS); within NHL as: 
mature B-cell lymphoma (BCL), mature T and natural killer-cell lymphoma (MT/NK) and other 
NHL; among BCL as: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), 
chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL), multiple myeloma 
and plasma cell neoplasm (MM/PCN) and other BCL, as detailed in Table 1. 
Exposure assessment. Habitual diet, including alcohol intake, during the year preceding 
recruitment was assessed at recruitment using validated center-specific self-reported dietary 
questionnaires.8 Data on anthropometry (self-reported in France and the UK Oxford center), 
physical activity, smoking habits, and prevalent chronic conditions were collected using 
lifestyle questionnaires.8 
A diet score was built from the combination of six dietary factors reflecting diet quality,7 i.e. 
cereal fibers, red and processed meat, the ratio of polyunsaturated to saturated fatty acids, 
margarine (to express industrially produced trans-fats), glycemic load, and fruits and 
vegetables. For each dietary factor, country-specific residuals were computed in models with 
total energy intake, grouped into country-specific deciles and scored from 0 to 9 with 0 being 
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the least healthy (i.e. high intake of red meat/processed meat, margarine, and glycaemic load, 
and low intake of fruits and vegetables, cereal fibres, and ratio of polyunsaturated to saturated 
fatty acids). Individual scores were summed up and categorized into quintiles. 
Definition of HLI. Scores of 0 to 4 were assigned to each individual variable category attributing 
larger values to the healthier behaviours for smoking (current smoking  > 15 cigarettes/day = 0, 
current smoking ≤15 cigarettes/day = 1, ex-smokers quit ≤ 10-years = 2, ex-smokers quit > 10 
years = 3, never smokers = 4), alcohol consumption (in g/day) at recruitment (>48 = 0, 24–
47.9= 1, 12–23.9 = 2, 6–11.9  = 3, and <6  = 4), diet score (1st quintile = 0 to the 5th quintile = 4), 
physical activity index (inactive=1, moderately inactive=2, moderately active=3, active=4), and 
body mass index at recruitment (BMI, kg/m2: >30= 0, 26–29.9 = 1, <22=2,  24–25.9 = 3, 22–
23.9=4). The final score was the arithmetic sum of the scores for each lifestyle factor and ranged 
from 1 to 20. 
Statistical analysis.  
The association between the HLI and the risk of lymphoma was evaluated using multivariable 
Cox proportional hazards models, with age as the primary time variable, and Breslow’s method 
to handle ties. The time at study entry was the age at recruitment, while the exit time was defined 
as the age at cancer diagnosis, death, loss to, or end of follow-up, whichever occurred first. All 
models were stratified by country,9 age at recruitment in 1-year categories and sex.  
The HLI was modelled as a continuous variable to compute HR estimates for a one-standard 
deviation (SD) corresponding to approximately 3 units in the score, and in quartiles using the 
second quartile as reference to avoid extreme comparisons within the HLI range. Models were 
systematically adjusted for education level (no degree/primary school, secondary/technical or 
professional school, longer education including university degree, unknown (4%)), height (cm, 
continuous), and energy intake from non-alcohol sources (kcal/day, continuous).  
Overall tests for statistical significance of HRs were determined by comparing Wald-test 
statistics to a χ² distribution with three degrees of freedom (dof) for HLI in categories (pWald) 
and one dof in continuous (ptrend). The assumption of proportional hazards (PH) was evaluated 
through the Schoenfeld’s residuals.10 
This article is protected by copyright. All rights reserved.
 
 
Potential departure from linearity in the association between HLI and HL risk was evaluated 
using restricted cubic splines11 and comparing the difference in log-likelihood of models with 
and without non-linear terms to a χ² distribution with two degrees of freedom. 
Sensitivity analyses were carried out by excluding, in turn, each factor from the HLI scores to 
identify factors mostly driving associations with each lymphoma subtype. The excluded 
component was used as a confounder in the model. Relationships between the HLI and 
lymphoma risks (HL and NHL) were examined by, in turn, sex, European region (North: 
Denmark, Norway, Sweden; Central: United Kingdom, The Netherlands, Germany; South: 
France, Greece, Italy, and Spain), and age at recruitment (<50, 50–60, ≥60 years old). 
Heterogeneity was evaluated by comparing the difference in log-likelihood of models with and 
without interaction terms between the HLI (continuous) and, in turn, sex, European region and 
age categories, to a χ² distribution with dof equal to the total number of interaction terms minus 
one. Heterogeneity of associations across BCL subtypes was evaluated through data-
augmentation by comparing the difference in log-likelihood of models with and without an 
interaction term between the HLI and an indicator variable for BCL subtypes to a χ² distribution 
with four dof.12 To address potential reverse causation, analyses were carried out excluding the 
first 2 and 5 years of follow-up. 
Two-sided p-values were determined with nominal statistical significance set to 5%. Analyses 
were performed using Stata version 14.13 




Study participants without lifestyle or dietary information (n=6,902), with a ratio of estimated 
energy intake to energy requirement in the top or bottom 1% (n=10,241), with self-reported 
prevalent cancer (n=24,221), with missing follow-up information (n=3,800) and with missing 
smoking status (n=15,685) or physical activity (n=8,824) were excluded. From a total of 
453,808 participants followed-up over 15 years (median), with a total of 6,328,639 person-
years, 2,999 incident lymphoma cases were diagnosed, including 2,746 NHL, 132 HL and 121 
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lymphomas NOS (Table 1). The HLI components and the confounding variables are described 
in Table 2. HLI was positively related to level of education and showed higher values in women 
than men. 
No association was observed between the HLI and the overall risk of lymphoma (Table 3). 
However, a 1-SD increase of HLI was inversely associated with HL risk (HR=0.78, 95%CI: 
0.66, 0.94; ptrend= 7.3e-03). The HRs for HL risk comparing the first, third and fourth quartile 
to the second quartile were 1.21 (0.78, 1.86), 0.64 (0.37, 1.09), and 0.64 (0.37, 1.10), 
respectively, with a significant trend across categories (pWald=0.03). The HLI was not associated 
with the risk of the major NHL subtypes (Table 3). The PH assumption was satisfied in each 
lymphoma subtype model. 
The HLI and HL risk dose-response relationship using restricted cubic splines presented limited 
evidence of departure from linearity (pnon-linearity= 0.42) (Online Supplementary Figure 1). 
Sensitivity analyses indicated that exclusion of smoking or diet from the HLI resulted in HL 
HRs for a 1-SD increase equal to 0.88 (95%CI: 0.71,1.10; ptrend=0.27) and 0.85 (0.69,1.04; 
ptrend=0.12), respectively (Online Supplementary Table 1). HRs for the other NHL subtypes 
were not altered after exclusion of, in turn, each lifestyle factors of the HLI. 
The associations between the HLI and lymphoma risk did not show evidence of heterogeneity 
by sex, European region and age at recruitment (results not shown). No evidence for 
heterogeneity was found across BCL subtypes (pheterogeneity=0.20). Exclusion of the first 2 and 5 
years of follow-up did not materially alter HR estimates (Online Supplementary Table 2). 
 
Discussion 
In a large European prospective study, a score combining five lifestyle factors was not 
associated with the risk of NHL. An inverse relationship was observed for HL, where smoking 
and, to a lesser extent, diet were the main drivers of the association.  
This study is one of the first attempts to investigate the risk of lymphoma with respect to 
modifiable lifestyle factors combined into a score. Within the NIH-AARP study, a score based 
on the American Cancer Society recommendations including physical activity, diet, BMI, 
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alcohol, but not smoking, yielded an inverse association between adherence to 
recommendations and HL risk. A 43% (95%CI: 2%,67%) lower risk of HL was observed when 
comparing the healthiest with the least healthy score category in an analysis including 113 HL 
cases, suggesting that lifestyle factors other than smoking may affect HL etiology, while no 
association was observed with NHL risk, consistently with findings in our study.14  
Smoking has been consistently positively associated with HL risk,15 with chronic exposure to 
cigarette smoking believed to promote and support lymphogenic microenvironment and affect 
immune cells through the impairment of T cells, natural killer cells, B cells and macrophages.16 
In our work, a comprehensive evaluation of the association between HLI and HL was 
undertaken via sensitivity analyses where each component of the lifestyle score was, in turn, 
removed from the HLI. Exclusion of smoking from HLI resulted in a null association suggesting 
that smoking was largely driving the association between lifestyle factors and HL risk.  
Although diet has been inconsistently related to HL,17 recent EPIC studies showed that dietary 
patterns reflecting Mediterranean and anti-inflammatory potential of diet were inversely 
associated with HL risk.18,19 In our sensitivity analysis a null association was consistently 
observed after the exclusion of diet from the HLI score, suggesting that diet could be involved 
in the HLI-HL relationship. Plausible biological mechanisms relating HL pathology to diet may 
involve inflammation pathways, possibly reflecting, among other factors, a diet rich in saturated 
fat, refined grains, red and processed meat, and high glycemic load.17,20 
Cumulative evidence points towards a positive relationship between obesity and HL21 which 
could be the consequence of an alteration of the immune response and stimulate low-grade 
chronic inflammation in adipose tissue.5 Alcohol intake has been repeatedly inversely 
associated with risks of HL and NHL, particularly with DLBCL, CLL and FL subtypes,6 a result 
that was partially attributed to reverse causation, as early symptoms of lymphomas may lead 
individuals to either quit or reduce their alcohol intake.22  
Current evidence suggests a role of lifestyle factors with respect to several NHL subtype risks. 
While smoking has been positively related to T-cell NHL,15 obesity has been related to an 
increase in diffuse large B-cell lymphoma (DLBC) and multiple myeloma (MM) risks,5 and a 
pro-inflammatory diet was positively associated with mature B-cell NHL.18 In this study, HLI 
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was not associated with the risk of NHL, either overall or within any of the NHL subtypes. 
Although HLI was inversely associated with the group of ‘other BCL’ (HR for a 1-SD increase 
in the HLI: 0.88; 95%CI: 0.79,1.00; ptrend=0.04), the associations of HLI across BCL subtypes 
was not heterogeneous (pheterogeneity=0.20). Despite the large size of the EPIC cohort, our study 
was possibly underpowered to detect likely weak associations of lifestyle habits with respect to 
lymphoma subtypes. Our results were not altered in sensitivity analyses that excluded, in turn, 
each lifestyle factor from the score. 
The strength of the current study relies on its prospective multi-country design, which included 
study populations with heterogeneous lifestyle habits. Among the limitations, we note that 
EPIC participants represent a healthy proportion of the general population and that risk 
estimates in our study were likely attenuated. In addition, our analyses did not account for 
potential changes in lifestyle habits during follow-up, potentially introducing bias in association 
estimates. These changes may have been the result of incident morbid conditions in ageing 
study population. Reverse causation could have biased some of our findings, by inducing 
changes of lifestyle behaviors before recruitment as a result of early symptoms. To partially 
address this, associations were minimally affected after exclusion of the first two and five years 
of follow-up. Furthermore, as pathological techniques for lymphoma ascertainment have 
developed continuously over the last decades, some of the cases of lymphoma subtypes may 
have been misclassified or simply missed. However, the most recent recommendations for 
lymphoma ascertainment were used in our study.1,23 Education was used as a proxy for socio-
economic status in the adjustment of the models, which may introduce residual confounding. 
Furthermore, the HLI score considered a selected list of lifestyle factors, each of which was 
given an equal weight. Information on occupation, pesticide exposure, history of participants’ 
infectious diseases (e.g. Human Immunodeficiency Virus, Epstein-Barr virus, and hepatitis 
viruses), which are known risk factors of lymphoma,24,25 would provide more informative 
insights of lymphoma etiology. However, information on these factors was available for a 
limited proportion of the EPIC cohort.  
In summary, in a large prospective study of European adults, adherence to a combination of 
healthy lifestyle habits was not associated with the risk of NHL and was inversely related to the 
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risk of HL, with smoking largely driving this association. These findings suggest a limited role 
of lifestyle factors in the etiology of lymphoma subtypes. However, the HLI accounts for five 
lifestyle habits, and other environmental factors like pesticides and occupational exposures 
might be relevant to lymphoma etiology.  
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Table 1. Country-specific distribution of study participants, lymphoma cases and the Healthy Lifestyle Index (HLI) in the EPIC cohort. 

































119 74 115 122 
 
11 (9-14) 




39 41 43 42 
 
13 (11-15) 




29 20 39 55 
 
12 (10-14) 




2 3 12 15 
 
11 (9-13) 




37 32 44 73 
 
11 (9-13) 




22 27 23 23 
 
13 (12-15) 




33 27 51 51 
 
12 (10-14) 




56 47 72 128 
 
12 (10-14) 




37 24 29 38 
 
13 (11-15) 




87 68 81 106 
 
13 (11-15) 
Total 453,808 6,328,639 15 2,999 2,746 132   2,290 125   461 363 509 653   12 (10-14) 
Abbreviations: PY, person-years; FUP, follow-up (years); HLI, healthy lifestyle index; NL, The Netherlands; PY, person-years; UK: United 
Kingdoms; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; BCL, mature B-cell lymphoma; MT/NK, Mature T and natural killer-cell 
lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; CLL/SLL, chronic lymphocytic leukemia, small lymphocytic 
leukemia and prolymphocytic lymphocytic leukemia ; MM/PCN, plasma cell neoplasm and multiple myeloma. 
1
 Median values; 
2
 The groups of overall number of lymphoma, NHL and BCL also included lymphomas not otherwise specified (n=121), other NHL subtypes 






















Table 2. Baseline characteristics
1





Q1 [1 - 10] Q2 [11 - 12] Q3 [13 - 14] Q4 [15 - 20]  
Total participants (n) 453,808 129,429 111,358 110,730 102,291 
Lymphoma cases (n) 2,999 937 734 718 610 
Index components 
     
Smoking (% never) 45 15 40 56 74 
Alcohol intake (g/day) 5 (1 - 15) 13 (3 - 30) 6 (1 - 15) 4 (1 - 11) 3 (0 - 7) 
BMI (kg/m²) 25 (22 - 28) 27 (24 - 30) 26 (22 - 28) 24 (22 - 27) 23 (22 - 25) 
Diet score (units) 27 (23 - 32) 23 (20 - 27) 26 (22 - 30) 28 (24 - 33) 32 (28 - 36) 
Physical activity (% active) 18 9 14 19 34 
Covariates 
     
Sex (% women) 70 56 71 77 80 
Age at recruitment (years) 52 (45 - 58) 52 (46 - 59) 52 (46 - 59) 51 (45 - 58) 50 (44 - 57) 
Energy intake from food (kcal/day) 1,921 (1,572 - 2,339) 1,964 (1,597 - 2,401) 1,918 (1,568 - 2,337) 1,901 (1,559 - 2,308) 1,896 (1,565 - 2,296) 
Height (cm) 165 (160 - 172) 167 (160 - 174) 165 (159 - 171) 165 (159 - 171) 165 (160 - 171) 












Table 3. Hazard ratio estimates
1
 for associations between the Healthy Lifestyle Index (HLI) (in quartiles and in continuous for a 1-SD increase
2
) 
and risks of lymphoma subtypes in the EPIC study. 
 HLI       







All lymphomas (n=2,999) 
        
n 937 734 718 610 
    
HR (95% CI) 1.04 (0.94 - 1.14) 1.00 (Ref) 1.02 (0.92 - 1.13) 0.97 (0.87 - 1.08) 0.68 
 
0.98 (0.94 - 1.01) 0.23 











        
n 53 36 22 21 
    
HR (95% CI) 1.21 (0.78 - 1.86) 1.00 (Ref) 0.64 (0.37 - 1.09) 0.64 (0.37 - 1.10) 0.03 
 
0.78 (0.66 - 0.94) 7.3E-03 
NHL (n=2,746) 
        
n 846 669 668 563 
    
HR (95% CI) 1.02 (0.92 - 1.14) 1.00 (Ref) 1.04 (0.93 - 1.16) 0.98 (0.88 - 1.10) 0.78 
 
0.99 (0.95 - 1.03) 0.50 
MT/NK (n=125) 
        
n 42 25 24 34 
    
HR (95% CI) 1.77 (0.62 - 5.01) 1.00 (Ref) 0.75 (0.49 - 1.14) 1.44 (0.85 - 2.44) 0.29 
 
1.04 (0.86 - 1.26) 0.68 
BCL (n=2,290) 
        
n 692 564 565 469 
    
HR (95% CI) 1.00 (0.89 - 1.11) 1.00 (Ref) 1.04 (0.93 - 1.17) 0.97 (0.85 - 1.09) 0.69 
 
0.99 (0.95 - 1.04) 0.81 
DLBCL (n=461) 
        
n 140 117 103 101 
    
HR (95% CI) 0.98 (0.76 - 1.25) 1.00 (Ref) 0.91 (0.7 - 1.19) 0.98 (0.75 - 1.28) 0.91 
 
0.99 (0.90 - 1.09) 0.84 
FL (n=363) 
        
n 88 92 97 86 
    
HR (95% CI) 0.82 (0.61 - 1.10) 1.00 (Ref) 1.04 (0.78 - 1.38) 0.98 (0.73 - 1.32) 0.44 
 
1.04 (0.93 - 1.16) 0.49 
CLL/SLL (n=509) 
        
n 171 100 127 111 
    
HR (95% CI) 1.33 (1.04 - 1.71) 1.00 (Ref) 1.35 (1.04 - 1.75) 1.34 (1.02 - 1.77) 0.08 
 
1.05 (0.96 - 1.15) 0.28 
MM/PCN (n=653) 
    
    
n 190 169 179 115 
    
HR (95% CI) 0.91 (0.74 - 1.13) 1.00 (Ref) 1.12 (0.91 - 1.38) 0.83 (0.65 - 1.05) 0.06 
 




        
n 103 86 59 56 
    
HR (95% CI) 0.96 (0.72 - 1.29) 1.00 (Ref) 0.71 (0.51 - 0.99) 0.75 (0.53 - 1.06) 0.12 
 
0.88 (0.79 - 1.00) 0.04 
 
Abbreviations: HLI, Healthy Lifestyle Index; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; MT/NK, Mature T and natural killer-cell 
lymphoma; BCL, mature B-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; CLL/SLL, chronic lymphocytic 
leukemia, small lymphocytic leukemia and prolymphocytic lymphocytic leukemia ; MM/PCN, plasma cell neoplasm and multiple myeloma. 
1
 Models were adjusted for education level, height, and non-alcohol energy intakes, and stratified by country, age in 1-year category, and sex; 











One standard deviation corresponded to 3 units in the HLI score; 
3 
P-values were determined using a Wald test for overall significance, according to a χ
2
 distribution with three degrees of freedom for evaluation 
by quartiles, and one degree of freedom for evaluation in continuous. 
4
 Other BCL includes Burkitt lymphoma, hairy cell leukemia, lymphoplasmacytic lymphoma, Mantle cell lymphoma, marginal zone lymphoma, 
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